cliffwatch

aprepitant · Heron Theraps Inc · NDA 216457

Aponvie

Earliest generic entry, as listed
18 Sep 2035

Blocked by patent: US 10500208, US 10624850, US 10953018, US 11173118, US 11744800, US 11878074, US 12115254, US 12115255, US 12290520, US 9561229, US 9808465, US 9974742, US 9974793, US 9974794.

Listed patents · 14 unexpired

PatentClaimsExpires
US 10500208product18 Sep 2035
US 10624850use U-344018 Sep 2035
US 10953018use U-344018 Sep 2035
US 11173118product18 Sep 2035
US 11744800product, use U-369018 Sep 2035
US 11878074use U-378718 Sep 2035
US 12115254product18 Sep 2035
US 12115255product18 Sep 2035
US 12290520product18 Sep 2035
US 9561229product, use U-344018 Sep 2035
US 9808465use U-344018 Sep 2035
US 9974742product18 Sep 2035
US 9974793product18 Sep 2035
US 9974794product, use U-344018 Sep 2035

Exclusivities · 0 unexpired

No unexpired exclusivities listed.

Paragraph IV certifications · 0

No Paragraph IV certification listed by FDA for this drug.

The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.

Event history

  • 25 Oct 2026First generic approved · 216457-001
  • 25 Oct 2026Generic approved · 216457-001

Products covered · 1

NDA · productFormStrengthListed expiry
216457 · 001 · RLDemulsion, intravenous32MG/4.4ML (7.2MG/ML)18 Sep 2035